Webinar Overview
Alzheimer’s disease (AD) is the most common type of dementia, and is a multifactorial neurodegenerative disease. While protein pathology related to beta-amyloid plaques and neurofibrillary tau deposits are observed in AD, early molecular alterations are not very clear yet, especially pathology related to the dysfunction of glymphatic clearance.
Kannie Chan discusses, how she and her team demonstrated that CEST MRI could identify an obvious decrease in CSF clearance at early stage of AD in a mouse model. Moreover, altered glucose uptake and kinetics in both CSF and parenchyma were detected. These alterations in multiple CEST parameters were not observed in normal age-matched mice. Together with deep-learning assisted CEST assessment of protein alterations, CEST MRI could provide additional multi-parametric assessments of AD pathology non-invasively.
On Demand Session